Last reviewed · How we verify
YL202
YL202 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
YL202 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.
At a glance
| Generic name | YL202 |
|---|---|
| Sponsor | MediLink Therapeutics (Suzhou) Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
SGLT2 is a protein responsible for glucose reabsorption in the kidneys. By inhibiting SGLT2, YL202 reduces glucose reabsorption, leading to increased glucose excretion in the urine and decreased blood glucose levels.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer (PHASE3)
- A Study of YL202 in Patients With Advanced Solid Tumors (PHASE2)
- Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer (PHASE3)
- A Study of YL202 in Selected Patients With Advanced Solid Tumors (PHASE2)
- A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer (PHASE1)
- A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YL202 CI brief — competitive landscape report
- YL202 updates RSS · CI watch RSS
- MediLink Therapeutics (Suzhou) Co., Ltd. portfolio CI